

# UC Davis

## Dermatology Online Journal

### Title

Amyloidosis cutis dyschromia: a rare form of primary cutaneous amyloidosis

### Permalink

<https://escholarship.org/uc/item/98g6s21m>

### Journal

Dermatology Online Journal, 20(4)

### Authors

Al-Dawsari, Najla A  
Shahab, Rana K

### Publication Date

2014

### DOI

10.5070/D3204022328

### Copyright Information

Copyright 2014 by the author(s). This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

## **Case Report**

### **Amyloidosis cutis dyschromia: a rare form of primary cutaneous amyloidosis**

**Najla A. Al-Dawsari MD FAAD, Rana K. Shahab MD FAAD**

**Dermatology Online Journal 20 (4): 5**

**Saudi Aramco Medical Services Organization, Saudi Arabia**

#### **Correspondence:**

Najla A Al-Dawsari  
Saudi Aramco Medical Services Organization  
Saudi Arabia  
Najla.aldawsari@gmail.com

## **Abstract**

Amyloidosis cutis dyschromia is a rare form of primary cutaneous amyloidosis. Amyloid deposition in the skin occurs without systemic manifestations and produces hypopigmented and hyperpigmented macules. A 19-year-old woman is presented with progression of this condition over 16 years.

## **Introduction**

Amyloidosis cutis dyschromia (ACD) also known as familial generalized dyschromic amyloidosis cutis is a rare disorder of pigmentation; the abnormal gene or locus is unknown. It is considered to be a type of primary cutaneous amyloidosis, which is characterized by the deposition of amyloid in the skin with absence of systemic deposits. To date, there are about 26 cases reported in the medical literature. Asians are affected more than other ethnic groups. The disease presents with mottled pigmentation formed by hyperpigmented and hypopigmented macules and patches in a generalized distribution [1-14]. We report a case of ACD with diffuse symmetrical involvement of the skin sparing the face, palms, and soles along with xerosis of the involved areas. Histopathology showed amorphous eosinophilic deposits in the papillary dermis that stained positive for Congo red.


## **Case synopsis**

A 19-year-old woman presented with progressive diffuse symmetric hyper and hypopigmented patches and macules that started to develop at the age of three years. The changes were asymptomatic and the patient denied any history of photosensitivity. Her past medical history was negative for any significant medical problems or disease. No history of prolonged or repeated infections could be elicited. The patient denied using any long-term medications, topical creams, or preparations before the onset of the skin changes. She had normal growth and development as a child. Her parents are first-degree cousins. One of her paternal aunts had a similar pattern of pigmentation.

Physical examination showed multiple hyperpigmented patches with intermingled multiple non-atrophic hypopigmented macules involving all the body, but sparing the face, palms, and soles. Some of the areas involved were dry and scaly (Figure 1-5). The dermatoglyphs were intact. No dental or nail abnormalities were noticed. Scalp and hair examination was within normal limits. Serum protein electrophoresis was negative and 24 hours urine collection for arsenic was within normal range. Skin biopsy from involved skin revealed eosinophilic globules in the papillary dermis (Figure 6-7). Congo red stain was positive (Figure 7-8). Topical emollients and steroids improved the skin dryness but not the dyschromia.



**Figures 1-4.** Hyperpigmented patches and macules with intermingled hypopigmented macules along with xerosis



**Figure 5.** HE X10: amorphous eosinophilic deposits (Amyloid) in the papillary dermis





Figure 7. Congo red stain: Amyloid deposits in the papillary dermas showing positive staining.

## Discussion

Primary cutaneous amyloidosis is a group of cutaneous disorders that are characterized by deposition of amyloid in the skin without deposition in any other organs [3]. ACD is a rare form of primary cutaneous amyloidosis that presents with diffuse hypo and hyperpigmented patches and macules with occasional itching. Onset is almost always before puberty [1-14]. Atrophy and blisters are rarely seen [4].

The disease is generally not associated with systemic symptoms. However, there is one case report in which ACD was associated with generalized morphea [5], and another case report involved two siblings suffering spasticity, motor weakness, and atypical Parkinsonism [6].

Histopathological examination shows amyloid deposits in the papillary dermis. Amyloid stains positive for crystal violet and Congo red. In rare instances, amyloid is not detected with the former stains and immunochemistry for anti-cytokeratin antibodies should be obtained if suspicion remains [1-4].

The pathogenesis is poorly understood but the disease is thought to be caused by an inherited increase in sensitivity to UVB leading to defects in DNA repair. Amyloid is formed as a result of keratinocyte degeneration [15].

Ozcan et al used oral acitretin (0.75 mg/kg/day for 3 months) with significant improvement in hyperpigmentation [7]. In another retrospective study published by Qiao et al, 10 patients were treated with oral vitamin E and vitamin C with minimal improvement. Three patients received 20 mg of oral acitretin daily for three months. A good response was observed in two of the three patients. Long term follow up of patients treated with acitretin was not published. No other treatments to date are successful to treat ACD [8].

Other causes of dyschromia should be excluded. The differential diagnosis is summarized in Table 1.

Table 1. Clinical differential diagnosis of ACD

Condition	Clinical Presentation	Associated features	Histopathology	Treatment	Other	References
<b>Congenital</b>						
Dyschromatosis universalis hereditaria	Generalized hyperpigmented and hypopigmented macules distributed in a reticulate pattern	Case reports of mental retardation, learning disabilities, seizures, eye abnormalities, deafness, insulin dependent diabetes and thrombocytopenia	Focal increase or decrease in melanin in the basal layer.	No treatment available Genetic Counseling	AD, AR	[16-18]
Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi)	Hyperpigmented and hypopigmented macules distributed on the face and the dorsal aspects of the extremities	Case reports of dental abnormalities, neurological abnormalities and hypo/hyperpigmented hairs	Increased/decreased melanin in hyperpigmented macules and hypopigmented macules respectively.	No treatment available Genetic counseling	AD, sporadic	[19,20]
Poikiloderma-like cutaneous amyloidosis	Poikilodermatous skin lesions, lichenoid papules, occasional blisters and palmoplantar keratosis	Short stature, photosensitivity	Amyloid deposition in the pigmented lesions and the lichenoid papules.	No treatment available Genetic counseling	AD, X-linked	[21-24]
Dyskeratosis congenita	Hyperpigmentation involving the upper chest and upper arms admixed with hypopigmented macules, occasional telangiectasias and epidermal atrophy, i.e. poikiloderma.	Leukoplakia, nail dystrophy, palmoplantar hyperhidrosis Dental, gastrointestinal, genitourinary, neurological, ophthalmic and skeletal abnormalities. Bone marrow failure Predisposition to hematological malignancies and squamous cell carcinoma	Epidermal thinning, telangiectasia, areas of increased pigment within the basal layer	No treatment available Genetic counseling	X-linked recessive 90% AD, AR <10 %	[25,26]
Xeroderma pigmentosum	Hyperpigmented macules in sun exposed skin (solar lentiginos)	Increased risk of skin cancers, ocular abnormalities, neurological abnormalities, developmental delays	Increased or decreased melanin in basal layer, epidermal atrophy or hyperkeratosis, solar elastosis	Photoprotection, oral retinoids	AR	[26-28]
<b>Acquired</b>						
Chronic arsenic toxicity	Hyperpigmented patches and macules 'rain-drop pigmentation', areas of depigmentation	Hyperkeratosis of palms and soles, cutaneous and internal malignancies	Basal cell pigmentation in hyperpigmented lesions.	Chelation therapy	Acquired	[29,30]

# Conclusion

We report a woman with ACD. Some of the conditions in the clinical differential diagnosis include cutaneous diseases presenting with congenital or acquired dyschromia (Table 1). The diagnosis of ACD may be suspected based upon the presence of progressive diffuse hypo and hyperpigmented patches and macules with or without itching before the onset of puberty. The diagnosis is confirmed by histopathological examination, which shows amyloid deposits in the papillary dermis that stain positively for amyloid stains such as crystal violet and Congo red. To date, a small number of patients have been successfully treated with acitretin. However, this was not an option in our patient or in women of childbearing potential.

# References

1. Madarasingha NP, Satgurunathan K, De Silva MV. A rare type of primary cutaneous amyloidosis: amyloidosis cutis dyschromica. *Int J Dermatol.* 2010 Dec;49(12):1416-8. [PMID: 21091677]
2. Huang WH, Wu CY, Yu CP, Chiang CP. Amyloidosis cutis dyschromica: four cases from two families. *Int J Dermatol.* 2009 May;48(5):518-21. [PMID: 19416385]
3. Schreml S, Szeimies RM, Vogt T, Landthaler M, Schroeder J, Babilas P. Cutaneous amyloidoses and systemic amyloidoses with cutaneous involvement. *Eur J Dermatol.* 2010 Mar-Apr; 20(2):152-60. [PMID: 20071301]
4. Yang W, Lin Y, Yang J, Lin W. Amyloidosis cutis dyschromica in two female siblings: cases report. *BMC Dermatol.* 2011 Feb 15;11:4. [PMID: 21320354]
5. Morales Callaghan AM, Vila JB, Fraile HA, Romero AM, Garcia GM. Amyloidosis cutis dyschromica in a patient with generalized morphea. *Br J Dermatol.* 2004;150:616–617. [PMID: 15030364]
6. Fernandes NF, Mercer SE, Kleinerman R, Lebowitz MG, Phelps RG. Amyloidosis cutis dyschromica associated with atypical Parkinsonism, spasticity and motor weakness in a Pakistani female. *J Cutan Pathol.* 2011 Oct;38(10):827-31. [PMID: 21645034]
7. Ozcan A, Senol M, Aydin NE, Karaca S. Amyloidosis cutis dyschromica: a case treated with acitretin. *J Dermatol.* 2005;32:474–477. [PMID: 16043923]
8. Qiao J, Fang H, Yao H. Amyloidosis cutis dyschromica. *Orphanet J Rare Dis.* 2012; 7: 95. [PMID: 23234252]
9. Ho MS, Ho J, Tan SH. Hypopigmented macular amyloidosis with or without hyperpigmentation. *Clin Exp Dermatol.* 2009; 34:e547–e551. [PMID: 19508574]
10. Eng AM, Cogan L, Gunnar RM, Blekys I. Familial generalized dyschromic amyloidosis cutis. *J Cutan Pathol.* 1976;3:102–108. [PMID: 993396]
11. Garg T, Chander R, Jabeen M, Barara M, Mittal K, Jain M, Puri V. Amyloidosis cutis dyschromica: a rare pigmentary disorder. *J Cutan Pathol.* 2011;38:823–826. [PMID: 21592180]
12. Wu CY, Yu CP, Chiang CP. Familial amyloidosis cutis dyschromica—a case report and review of the literature. *Dermatol Sinica.* 2008;26:16–21. [PMID:19416385]
13. Choonhakarn C, Wittayachanyapong S. Familial amyloidosis cutis dyschromica: six cases from three families. *J Dermatol.* 2002;29:439–442. [PMID: 12184644]
14. Vijaikumar M, Thappa DM. Amyloidosis cutis dyschromica in two siblings. *Clin Exp Dermatol.* 2001;26:674–676. [PMID: 11722454]
15. Moriwaki S, Nishigori C, Horiguchi Y, Imamura S, Toda K, Takebe H. Amyloidosis cutis dyschromica. DNA repair reduction in the cellular response to UV light. *Arch Dermatol.* 1992 Jul;128(7):966-70. [PMID: 1626966]
16. Al Hawsawi K, All Aboud K, Ramesh V, Al Aboud D: Dyschromatosis universalis hereditaria: report of a case and review of the literature. *Pediatr Dermatol* 2002; 19:523-526. [PMID: 12437556]
17. Pirasath S, Sundaresan T, Tamilvannan T. Thrombocytopenia in dyschromatosis universalis hereditaria. *Ceylon Med J.* 2012 Sep;57(3):124-5. [PMID: 23086030]
18. Tojyo K, Hattori T, Sekijima Y, Yoshida K, Ikeda S. A case of idiopathic brain calcification associated with dyschromatosis symmetrica hereditaria, aplasia of dental root, and aortic valve sclerosis. *Rinsho Shinkeigaku.* 2001 Jun; 41(6):299-305. [PMID: 11771159]
19. Kantaputra PN, Chinadet W, Ohazama A, Kono M. Dyschromatosis symmetrica hereditaria with long hair on the forearms, hypo/hyperpigmented hair, and dental anomalies: report of a novel ADAR1 mutation. *Am J Med Genet A.* 2012 Sep;158A(9):2258-65. [PMID: 22821605]
20. Oyama M, Shimizu H, Ohata Y, et al: Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. *Br J Dermatol* 1999; 140:491-496. [PMID: 10233273]
21. Pardo Arranz L, Escalonilla Garcia-Patos P, Roman Curto C, Blanco Barrios S, Fernandez Lopez E, de Unamuno Perez P. Familial poikylodermic cutaneous amyloidosis. *Eur J Dermatol.* 2008;18:289–291. [PMID: 18474457]
22. Rajagopalan K, Tay CH. Familial lichen amyloidosis: report of 19 cases in 4 generations of a Chinese family in Malaysia. *Br J Dermatol.*1972; 87: 123-9. [PMID: 5057380]
23. Newton JA, Jagjivan A, Bhogal B, McKee PH, McGibbon DH. Familial primary cutaneous amyloidosis. *Br J Dermatol.* 1985; 112: 201-8. [PMID: 3970841]
24. Partington MW, Prentice RSA. X-linked cutaneous amyloidosis: further clinical and pathological observations. *Am J Med Genet* 1989; 32: 115-9. [PMID: 2705473]
25. Knight S, Vulliamy T, Copplestone A, et al: Dyskeratosis Congenita (DC) Registry: identification of new features of DC. *Br J Haematol* 1998; 103:990-996. [PMID: 9886310]

26. Ronald P Rapini. Practical Dermatopathology. 1st ed. Elsevier Inc. 2005.
27. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol. 1987;123:241–250. [PMID: 3545087]
28. Bettoli V, Zauli S, Virgili A. Retinoids in the chemoprevention of non-melanoma skin cancers: why, when and how. J Dermatolog Treat. 2013 Jun;24(3):235-7. [PMID: 23148804]
29. Sengupta SR, Das NK, Datta PK. Pathogenesis, clinical features and pathology of chronic arsenicosis. Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):559-70. [PMID: 19171978]
30. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003 Jul; 79 (933) 391-6. [PMID: 12897217]